LISA KENDALL: Open Payments
NPI 1720077134 · DUNEDIN, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,505 in 14 payments from 9 companies in 2025. Trend: 2023 $1,180 · 2024 $1,144 · 2025 $1,505
Food & beverage: $1,505
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 3 | $365 |
| Teva Pharmaceuticals USA, Inc. | 2 | $259 |
| ACADIA Pharmaceuticals Inc | 2 | $239 |
| ARGENX US, INC. | 2 | $212 |
| Smith+Nephew, Inc. | 1 | $150 |
| Otsuka America Pharmaceutical, Inc. | 1 | $120 |
| Neurocrine BioSciences, Inc. | 1 | $116 |
| AtriCure, Inc. | 1 | $29 |
| Cipher Pharmaceuticals US LLC | 1 | $14 |
Products named: AUSTEDO XR, NUPLAZID, VYVGART, COLLAGENASE SANTYL, REXULTI, Briviact, Fintepla, INGREZZA.
Industry payments across FL — which companies pay providers there.
